Johnson & Johnson (JNJ) DIvidends Date & History

Key Takeaways

• Dividend yield: Johnson & Johnson offers a dividend yield of roughly 2.1%, based on an annual payout of $5.36 per share.
• Dividend growth streak: The company has raised its dividend for 64 consecutive years, placing it among the elite group known as Dividend Kings.
• Payment schedule: Dividends are paid quarterly, with a most recent payment of $1.34 per share.
• Payout ratio: The payout ratio sits near 62% of earnings, a level that remains manageable for a mature healthcare leader.
• Investor appeal: JNJ is best characterized as a reliable dividend growth stock rather than a high-yield income play.

Dividend Overview

Johnson & Johnson, one of the world's largest diversified healthcare companies, maintains a disciplined and shareholder-friendly dividend policy. The company pays its dividend on a quarterly basis, currently at $1.34 per share, which translates to an annualized dividend of $5.36 per share and a dividend yield of approximately 2.1% based on recent trading levels.

While this yield is modest compared to some of its pharmaceutical peers, Johnson & Johnson is widely regarded as a premier dividend growth stock rather than a high-yield play. The company's reputation rests on the remarkable consistency of its payouts and its ability to increase them year after year across changing economic conditions. For investors seeking steady, compounding income with a long track record, Johnson & Johnson's dividend profile is among the most dependable in the healthcare sector.

Dividend History and Growth

Johnson & Johnson's dividend history is one of the longest and most consistent in corporate America. The company has increased its dividend for 64 consecutive years, a feat achieved by fewer than 50 publicly traded companies. This distinction earns it the title of "Dividend King" — a term reserved for companies that have raised their dividend every year for at least 50 consecutive years.

In April 2026, the board approved a 3.1% increase, lifting the quarterly payout from $1.30 to $1.34 per share. Over the past five years, the company's dividend has grown at an annualized rate of roughly 5.25%. Historically, increases have been steady and measured rather than dramatic, reflecting management's commitment to sustainable, long-term payout growth. The company has never cut its dividend during this extraordinary streak, underscoring the durability of its business model.

Dividend Sustainability and Payout Ratio

The sustainability of Johnson & Johnson's dividend is supported by a payout ratio of approximately 62% based on trailing twelve-month earnings. When measured against free cash flow, the payout is even more conservative at roughly 40%, indicating that the dividend is well covered by the company's actual cash generation.

Johnson & Johnson benefits from a diversified revenue base spanning pharmaceuticals, medical devices, and consumer health, which provides multiple cash flow streams and reduces dependence on any single product or market. The company also maintains a strong balance sheet and an investment-grade credit rating, giving it ample financial flexibility to continue funding both its dividend and strategic investments. While the payout ratio has edged higher relative to its three-year average, it remains well within a sustainable range for a mature, cash-rich healthcare enterprise.

Dividend Compared to Industry Peers

Within the healthcare and pharmaceutical sector, Johnson & Johnson's dividend yield of about 2.1% is below the industry median, which typically ranges between 2.5% and 2.8%. Several large-cap peers offer notably higher yields — Pfizer (PFE) and Bristol Myers Squibb (BMY) often yield above 5%, while AbbVie (ABBV) and Merck (MRK) typically yield between 3% and 4%.

However, Johnson & Johnson differentiates itself through the length of its dividend growth streak. Few, if any, of its direct peers can match 64 consecutive years of increases. Investors effectively accept a lower starting yield in exchange for exceptional reliability, diversification across healthcare segments, and a proven history of compounding payout growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Explore the AI Screener to streamline your research and uncover investment ideas aligned with your strategy.

Is This Stock Attractive for Dividend Investors?

Johnson & Johnson is most likely to appeal to dividend growth investors and long-term, conservative investors who prioritize reliability and compounding over a high current yield. The 64-year streak of annual increases makes it a foundational holding for those building a growing income stream over decades.

For income investors who require a higher immediate yield, JNJ's roughly 2.1% payout may be less compelling than alternatives in the pharmaceutical sector. Similarly, investors seeking rapid dividend growth may find the mid-single-digit annual increases to be moderate rather than aggressive.

Overall, Johnson & Johnson's dividend is defined by durability rather than spectacle. It is best suited to investors who value consistency, financial strength, and the reassurance of a payout that has survived — and grown through — more than six decades of market cycles. As with any investment, individual suitability depends on personal goals, time horizon, and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations